Sun Pharm Inds Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUN PHARM INDS INC, and when can generic versions of SUN PHARM INDS INC drugs launch?
SUN PHARM INDS INC has ninety-seven approved drugs.
There are eleven US patents protecting SUN PHARM INDS INC drugs. There are two tentative approvals on SUN PHARM INDS INC drugs.
There are thirty-seven patent family members on SUN PHARM INDS INC drugs in thirteen countries and one hundred and twenty-nine supplementary protection certificates in sixteen countries.
Summary for Sun Pharm Inds Inc
| International Patents: | 37 |
| US Patents: | 11 |
| Tradenames: | 83 |
| Ingredients: | 80 |
| NDAs: | 97 |
Drugs and US Patents for Sun Pharm Inds Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | DEXMETHYLPHENIDATE HYDROCHLORIDE | dexmethylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206734-004 | Nov 5, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds Inc | ALLOPURINOL | allopurinol | TABLET;ORAL | 078390-002 | Aug 30, 2007 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | BENZONATATE | benzonatate | CAPSULE;ORAL | 040587-001 | Mar 19, 2008 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sun Pharm Inds Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-006 | Aug 15, 2014 | 9,078,925 | ⤷ Subscribe |
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | 8,758,418 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-002 | May 25, 2012 | 9,089,534 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUN PHARM INDS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 30 mg and 40 mg | ➤ Subscribe | 2012-12-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2016-05-16 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-01-07 |
| ➤ Subscribe | Capsules | 35 mg | ➤ Subscribe | 2015-11-25 |
International Patents for Sun Pharm Inds Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2020267186 | ⤷ Subscribe |
| Australia | 2023201112 | ⤷ Subscribe |
| Mexico | 2021014175 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sun Pharm Inds Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0443983 | C300445 | Netherlands | ⤷ Subscribe | PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016 |
| 1412357 | C 2008 016 | Romania | ⤷ Subscribe | PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408 |
| 1412357 | SPC/GB08/040 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
